BioDelivery Sciences International, Inc. (BDSI)
(Delayed Data from NSDQ)
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Mylan (MYL) Q2 Earnings: Is a Disappointment in the Cards?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars along with other updates from Mylan's (MYL) pipeline, when it reports Q2 results (scheduled for Aug 8).
Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?
by Zacks Equity Research
Prothena's (PRTA) Q2 results are likely to reflect pipeline updates along with progress with its restructuring plan.
Envision Healthcare (EVHC) Q2 Earnings: What's in Store?
by Zacks Equity Research
Envision Healthcare (EVHC) Q2 earnings should gain from higher revenues from thePhysician Service segment and gains from cost control initiatives.
Is a Beat in the Cards for Nektar (NKTR) in Q2 Earnings?
by Zacks Equity Research
Nektar Therapeutics (NKTR) is likely to beat estimates when it reports second-quarter results. Investors are expected to focus on pipeline progress.
Is a Beat in Store for Radius Health (RDUS) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on lead drug Tymlos' uptake and an update on Radius Health's (RDUS) marketing application for the drug in Europe, when it reports second-quarter results on Aug 7.
What Lies in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology is expected to drive milestone and royalty payments in second-quarter 2018.
What's in the Cards for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
On Conatus' (CNAT) second-quarter 2018 conference call, investor focus will remain on the company's progress with respect to its lead candidate, emricasan.
What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?
by Zacks Equity Research
On Agios' (AGIO) second-quarter 2018 conference call, investor focus is likely to be on the launch preparations of the company's newly FDA approved leukemia drug, Tibsovo.
Teva (TEVA) Q2 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales in the second quarter. On the call, management is likely to comment on the launch preparation for pegvaliase.
What's in Store for Celldex (CLDX) This Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex Pharma (VRTX) is expected to beat estimates when it reports second-quarter earnings on Jul 25.
BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.
Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
by Ekta Bagri
Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.
What's in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.
5 Biotech Stocks Set to Beat Estimates This Earnings Season
by Zacks Equity Research
Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.
BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report?
by Zacks Equity Research
BioDelivery Sciences (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Shares of BioDelivery Sciences (BDSI) rose over 5% yesterday.
BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y
by Zacks Equity Research
BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Arena's (ARNA) only approved product, Belviq, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q4.
What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?
by Zacks Equity Research
BioDelivery's (BDSI) lead drugs Belbuca and Bunavail look promising to deliver an earnings beat in Q4.
Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.